Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Confere...
With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which pa...